NEW YORK (GenomeWeb) – New research suggests that an immune checkpoint protein called VISTA may serve as a target for future immunotherapy development in pancreatic ductal adenocarcinoma (PDAC), which is known for its poor outcomes and resistance to existing immune checkpoint therapies that target proteins such as PD-1 or CTLA4.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.